Please wait a minute...
文章检索
预防医学  2021, Vol. 33 Issue (1): 25-30    DOI: 10.19485/j.cnki.issn2096-5087.2021.01.006
  论著 本期目录 | 过刊浏览 | 高级检索 |
2005—2019年伊犁州抗病毒治疗吸毒人群HIV/AIDS病例生存分析
周涛1, 李月飞1, 白雪1, 胡晓远2, 马媛媛2, 倪明健2
1.新疆医科大学公共卫生学院,新疆 乌鲁木齐 830011;
2.新疆维吾尔自治区疾病预防控制中心性病/艾滋病预防控制中心
Survival analysis of HIV/AIDS patients with antiretroviral therapy among drug users in Yili Prefecture from 2005 to 2019
ZHOU Tao*, LI Yuefei, BAI Xue, HU Xiaoyuan, MA Yuanyuan, NI Mingjian
*School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang 830011, China
全文: PDF(888 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析2005—2019年新疆维吾尔自治区伊犁州接受抗病毒治疗(HAART)的吸毒人群HIV/AIDS病例生存情况及影响因素,为降低艾滋病死亡率提供依据。方法 通过艾滋病抗病毒治疗信息系统收集2005—2019年伊犁州HAART治疗吸毒人群HIV/AIDS病例的人口学信息、临床分期、基线CD4+T淋巴细胞(CD4细胞)水平和治疗情况等资料,采用寿命表法估计生存率,采用Cox比例风险回归模型分析生存时间的影响因素。结果 2005—2019年共纳入HIV/AIDS病例1 935例,初始HAART治疗年龄中位数为37岁,CD4细胞中位数为293个/μL。第1、5、7和10年累积生存率分别为97%、78%、73%和66%。多因素Cox比例风险回归分析结果显示,体质指数(BMI)为18.5~<28.0 kg/m2HR:0.391~0.656,95%CI:0.234~0.958)、基线CD4细胞水平>200个/μL(HR:0.354~0.667,95%CI:0.232~0.841)、近7 d未漏服药物(HR=0.009,95%CI:0.001~0.061)的HIV/AIDS病例死亡风险较低;WHO临床分期为Ⅱ~ Ⅳ期(HR:1.479~2.311,95%CI:1.004~3.288)、治疗延迟时间≥1年(HR:1.287~1.388,95%CI:1.029~1.826)的HIV/AIDS病例死亡风险较高。结论 伊犁州HAART治疗吸毒人群HIV/AIDS病例5年累积生存率为78%;BMI、基线CD4细胞水平、WHO临床分期、治疗延迟时间、近7 d漏服药物是其生存时间的影响因素。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
周涛
李月飞
白雪
胡晓远
马媛媛
倪明健
关键词 艾滋病吸毒人群抗病毒治疗生存分析    
AbstractObjective To understand the survival status and influencing factors of HIV/AIDS patients with highly active antiretroviral therapy ( HAART ) among drug users in Yili Prefecture, Xinjiang from 2005 to 2019, so as to provide references for reducing AIDS mortality. Methods The demographic information, clinical stage, baseline CD4+T lymphocyte ( CD4 ) level and treatment status of HIV/AIDS patients with HAART in Yili Prefecture from 2005 to 2019 were collected through AIDS Antiretroviral Therapy Information System. The survival rate was calculated by the life table method. The influencing factors for survival time were analyzed by Cox proportional hazard regression model. Results Totally 1 935 patients were recruited, the median age receiving HAART was 37 years old and the median CD4 counts was 293/μL. The cumulative survival rates at 1, 5, 7 and 10 years were 97%, 78%, 73%, and 66%, respectively. The multivariate Cox proportional hazards regression analysis showed that the patients with body mass index of 18.5-<28.0 kg/m2 ( HR: 0.391-0.656, 95%CI: 0.234-0.958 ), baseline CD4>200/μL ( HR: 0.354-0.667, 95%CI: 0.232-0.841 ) , or missed medication in the last 7 days ( HR=0.009, 95%CI: 0.001-0.061 ) had lower risk of death; the patients with WHO clinical stage of Ⅱ-Ⅳ ( HR: 1.479-2.311, 95%CI: 1.004-3.288 ) or treatment delay ≥1 years ( HR: 1.287-1.388, 95%CI: 1.029-1.826 ) had higher risk of death. Conclusions The 5-year cumulative survival rate of HIV/AIDS patients with HAART in Yili Prefecture is 78%. Body mass index, baseline CD4 level, WHO clinical stage, treatment delay and missed medication in last 7 days were the influencing factors for survival time.
Key wordsacquired immunodeficiency syndrome    drug users    antiretroviral therapy    survival analysis
收稿日期: 2020-08-03      出版日期: 2021-01-14
ZTFLH:  R512.91  
基金资助:新疆防治艾滋病规模化现场流行病学干预研究(2018ZX10715007)
通信作者: 倪明健,E-mail:xjnmj@126.com   
作者简介: 周涛,硕士在读
引用本文:   
周涛, 李月飞, 白雪, 胡晓远, 马媛媛, 倪明健. 2005—2019年伊犁州抗病毒治疗吸毒人群HIV/AIDS病例生存分析[J]. 预防医学, 2021, 33(1): 25-30.
ZHOU Tao, LI Yuefei, BAI Xue, HU Xiaoyuan, MA Yuanyuan, NI Mingjian. Survival analysis of HIV/AIDS patients with antiretroviral therapy among drug users in Yili Prefecture from 2005 to 2019. Preventive Medicine, 2021, 33(1): 25-30.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2021.01.006      或      http://www.zjyfyxzz.com/CN/Y2021/V33/I1/25
[1] ALVAREZ P A,VALERIO J E,SWEDBERG H N,et al.Highly active antiretroviral therapy and gamma knife radiosurgery for the treatment of AIDS-related primary central nervous system lymphoma[J].World Neurosurg,2019,124(16):310-312.
[2] ORTBLAD K F,BAETEN J M,CHERUTICH P,et al.The arc of HIV epidemics in sub-Saharan Africa:new challenges with concentrating epidemics in the era of 90-90-90[J].Curr Opin HIV AIDS,2019,14(5):354-365.
[3] 杨爱学,陈涛,刘伟.新疆伊犁州直1996—2015年艾滋病病例死亡情况分析[J].中国艾滋病性病,2016,22(10):788-790.
[4] 倪明健,陈学玲,胡晓远,等.新疆维吾尔自治区艾滋病抗病毒治疗者死亡率及其影响因素分析[J].中华预防医学杂志,2014,48(11):953-958.
[5] 中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].4版.北京:人民卫生出版社,2016.
[6] 豆智慧,张福杰,赵燕,等.2002—2014年中国免费艾滋病抗病毒治疗进展[J].中华流行病学杂志,2015,36(12):1345-1350.
[7] 刘芳,施雅莹,吴学庆,等.经性传播艾滋病患者抗病毒治疗的生存分析[J].中国社会医学杂志,2015,32(6):480-483.
[8] DAMTEW B,MENGISTIE B,ALEMAYEHU T.Survival and determinants of mortality in adult HIV/AIDS patients initiating antiretroviral therapy in Somali Region,Eastern Ethiopia[J].Pan Afr Med J,2015,22:138-143.
[9] NAIDOO K,YENDE Z N,AUGUSTINE S.A retrospective cohort study of body mass index and survival in HIV infected patients with and without TB co-infection[J].Infect Dis Poverty,2018,7(1):35-46.
[10] SHOKO C,CHIKOBYU D.A superiority of viral load over CD4 cell count when predicting mortality in HIV patients on therapy[J].BMC Infect Dis,2019,19(1):169.
[11] BAJPAI R,CHATURVEDI H,JAYASEELAN L,et al.Effects of antiretroviral therapy on the survival of human immunodeficiency virus-positive adult patients in Andhra Pradesh,India:a retrospective cohort study,2007-2013[J].J Prev Med Public Health,2016,49(6):394-405.
[12] 王斌,龚德光,朱洁群.鄞州区艾滋病抗病毒治疗患者生存率及影响因素分析[J].预防医学,2020,32(4):346-350.
[13] LODI S,GUNTHARD,HULDRYCH F,et al.Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance[J].AIDS,2018,32(3):327-335.
[14] 陈亮,连巧龄,刘美增.福建省1987—2018年HIV/AIDS病例生存情况及其影响因素分析[J].中国公共卫生,2019,35(12):1623-1627.
[15] SHARMA S,SCHLUSSER K E,TORRE P,et al.The benefit of immediate compared with deferred antiretroviral therapy on CD4 cell count recovery in early HIV infection[J].AIDS,2019,33(8):1335-1344.
[16] ADEOTI A O,DADA M,ELEBIYO T,et al.Survey of antiretroviral therapy adherence and predictors of poor adherence among HIV patients in a tertiary institution in Nigeria[J].Pan Afr Med J,2019,33:277-283.
[17] 陈军,曹晓斌,张波,等.云南省两地抗病毒治疗门诊注射吸毒HIV感染者入组美沙酮维持治疗的影响因素分析[J].中华流行病学杂志,2016,37(1):68-71.
[18] 周莹,卢静,张之,等.江苏省艾滋病一线药物抗病毒治疗失败病人的耐药特征及影响因素分析[J].中华疾病控制杂志,2017,21(12):1191-1194.
[19] 朱晓艳,王国永,孙晓光,等.山东省抗病毒治疗的HIV/AIDS病人的耐药调查结果分析[J].中国艾滋病性病,2017,23(2):107-111.
[20] EYASSU M A,MOTHIBA T M,MBAMBO NP.Adherence to antiretroviral therapy among HIV and AIDS patients at the Kwa-Thema clinic in Gauteng Province,South Africa[J].Afr J Prim Health Care Fam Med,2016,8(2):e1-e7.
[21] FONSAH J Y,NJAMNSHI A K,KOUANFACK C,et al.Adherence to antiretroviral therapy(ART)in Yaoundé-Cameroon:association with opportunistic infections,depression,ART regimen and side effects[J].PLoS One,2017,12(1):e17-e23.
[1] 王建英, 卢巧玲, 许树红, 杨作凯, 单杏仁. 绍兴市新报告50岁及以上HIV/AIDS病例特征[J]. 预防医学, 2021, 33(1): 61-66.
[2] 张宏, 陈剑惠, 刘梅艳, 何鼎盛. 2011—2019年福州市经性接触传播的男性HIV/AIDS病例特征[J]. 预防医学, 2020, 32(9): 907-910.
[3] 罗艳, 赵刚, 黄思超, 罗文杰, 李西婷, 丁建明. 2013—2018年杭州市HIV/AIDS病例检测发现与晚发现影响因素研究[J]. 预防医学, 2020, 32(8): 757-761.
[4] 蒋均, 罗明宇, 杨介者, 何林, 徐云, 周欣. 2015—2019年浙江省新确证50岁及以上HIV/AIDS病例流行特征分析[J]. 预防医学, 2020, 32(8): 762-766.
[5] 王瑞, 张海兰, 黄晓丹, 卫晓丽. 西安市性病门诊男性就诊者艾滋病和性病监测结果[J]. 预防医学, 2020, 32(8): 813-816.
[6] 邱玉冰, 许琳, 杨蕊, 陈金瓯. 云南省成功治疗肺结核患者5年复发情况及影响因素分析[J]. 预防医学, 2020, 32(6): 559-562.
[7] 丁坚强, 项琼珊, 陈婉君, 刘巨敏. 镇海区性病患者HIV抗体检测及影响因素分析[J]. 预防医学, 2020, 32(6): 618-620.
[8] 王斌, 龚德光, 朱洁群. 鄞州区艾滋病抗病毒治疗患者生存率及影响因素分析[J]. 预防医学, 2020, 32(4): 346-350.
[9] 唐慧玲, 蒋均, 罗明宇, 金屡华, 王凤英, 潘晓红. 金华市2017年新确诊性接触传播HIV/AIDS本地感染病例特征及影响因素分析[J]. 预防医学, 2020, 32(4): 355-360.
[10] 张兴亮, 罗艳, 丁建明, 吴虹, 蒋均. 2017年杭州市新确诊男男性行为人群HIV/AIDS病例特征分析[J]. 预防医学, 2020, 32(4): 373-377.
[11] 卢江炜, 汤雪娟. 嘉兴市HIV感染孕产妇特征及艾滋病母婴阻断分析[J]. 预防医学, 2020, 32(4): 405-407.
[12] 陈卫永, 潘晓红, 杨介者, 蒋均, 姜婷婷, 陈琳, 陈婉君, 王憓, 周欣, 马瞧勤. 浙江省第三轮艾滋病综合防治示范区评估结果[J]. 预防医学, 2020, 32(3): 240-244.
[13] 邓小芳, 岑平, 唐驰, 徐红, 林倩, 农丽萍, 钟永泉, 李斯斯, 姚敏. 南宁市新报告HIV/AIDS病例CD4+T淋巴细胞首次检测结果分析[J]. 预防医学, 2020, 32(3): 270-273.
[14] 赵晨飞, 朱明利, 师金川, 喻剑华. 艾滋病抗病毒治疗对HIV-1感染者肠道微生态的影响[J]. 预防医学, 2020, 32(3): 274-278.
[15] 艾克丹·塔西, 马媛媛, 胡晓远, 倪祯, 倪明健. 乌鲁木齐市男男性行为人群HIV新发感染及影响因素分析[J]. 预防医学, 2020, 32(3): 278-281.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed